|
Report Date : |
11.03.2014 |
IDENTIFICATION DETAILS
|
Name : |
KYOTO PHARMA INDUSTRIAL CO LTD |
|
|
|
|
Registered Office : |
7-8 Nihombashi-Kobunacho Chuoku Tokyo
103-0024 |
|
|
|
|
Country : |
Japan |
|
|
|
|
Financials (as on) : |
31.03.2013 |
|
|
|
|
Date of Incorporation : |
July 1952 |
|
|
|
|
Com. Reg. No.: |
0100-01-041474 |
|
|
|
|
Legal Form : |
Limited Company (Kabushiki Kaisha) |
|
|
|
|
Line of Business : |
Manufacturer of pharmaceuticals for medical-use |
|
|
|
|
No. of Employees : |
291 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
Maximum Credit Limits : |
Yen 335.7 Million |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2013
|
Country Name |
Previous Rating (30.06.2013) |
Current Rating (30.09.2013) |
|
Japan |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
JAPAN - ECONOMIC OVERVIEW
In the years following World War II, government-industry cooperation, a strong work ethic, mastery of high technology, and a comparatively small defense allocation (1% of GDP) helped Japan develop a technologically advanced economy. Two notable characteristics of the post-war economy were the close interlocking structures of manufacturers, suppliers, and distributors, known as keiretsu, and the guarantee of lifetime employment for a substantial portion of the urban labor force. Both features are now eroding under the dual pressures of global competition and domestic demographic change. Japan's industrial sector is heavily dependent on imported raw materials and fuels. A small agricultural sector is highly subsidized and protected, with crop yields among the highest in the world. While self-sufficient in rice production, Japan imports about 60% of its food on a caloric basis. For three decades, overall real economic growth had been spectacular - a 10% average in the 1960s, a 5% average in the 1970s, and a 4% average in the 1980s. Growth slowed markedly in the 1990s, averaging just 1.7%, largely because of the after effects of inefficient investment and an asset price bubble in the late 1980s that required a protracted period of time for firms to reduce excess debt, capital, and labor. Modest economic growth continued after 2000, but the economy has fallen into recession three times since 2008. A sharp downturn in business investment and global demand for Japan's exports in late 2008 pushed Japan into recession. Government stimulus spending helped the economy recover in late 2009 and 2010, but the economy contracted again in 2011 as the massive 9.0 magnitude earthquake and the ensuing tsunami in March disrupted manufacturing. The economy has largely recovered in the two years since the disaster, but reconstruction in the Tohoku region has been uneven. Newly-elected Prime Minister Shinzo ABE has declared the economy his government's top priority; he has pledged to reconsider his predecessor's plan to permanently close nuclear power plants and is pursuing an economic revitalization agenda of fiscal stimulus and regulatory reform and has said he will press the Bank of Japan to loosen monetary policy. Measured on a purchasing power parity (PPP) basis that adjusts for price differences, Japan in 2013 stood as the fourth-largest economy in the world after second-place China, which surpassed Japan in 2001, and third-place India, which edged out Japan in 2012. The new government will continue a longstanding debate on restructuring the economy and reining in Japan's huge government debt, which exceeds 225% of GDP. Persistent deflation, reliance on exports to drive growth, and an aging and shrinking population are other major long-term challenges for the economy
|
Source
: CIA |
KYOTO PHARMA INDUSTRIAL CO LTD
REGD NAME: Kyokuto
Seiyaku Kogyo KK
MAIN OFFICE: 7-8
Nihombashi-Kobunacho Chuoku Tokyo 103-0024 JAPAN
Tel:
03-5645-5661
Fax: 03-5645-5705
*..
The given address is its Ibaraki Factory
URL: http://www.kyokutoseiyaku.co.jp
E-Mail address: (thru the URL)
Mfg of
pharmaceuticals for medical-use
Sapporo, Sendai,
Nagoya, Osaka, Hiroshima, Fukuoka
USA
Takahagi
(Ibaraki), as given
HIROSHI KIKUCHI,
PRES Akinari
Miwa, adv
Masaaki Sasajima,
dir Keiji
Tomii, dir
Katsushi Harada,
dir Masaru
Noriki, dir
Yen Amount: In million Yen, unless
otherwise stated
FINANCES FAIR A/SALES Yen
9,441 M
PAYMENTS NO COMPLAINTS CAPITAL Yen
783 M
TREND UP WORTH Yen
6,705 M
STARTED 1952 EMPLOYES 291
MFR OF MEDICAL-USE PHARMACEUTICALS.
FINANCIAL SITUATION CONSIDERED FAIR AND GOOD
FOR ORDINARY BUSINESS ENGAGEMENTS.
MAX CREDIT LIMIT:
YEN 335.7 MILLION, 30 DAYS NORMAL TERMS
The subject company was established by Tarukichi Kikuchi in order to
make most of his experience in the subject line of business. This is a special mfr of medical-use
pharmaceuticals (See OPERATION). Goods are exported. Clients include pharmaceutical makers,
hospitals, universities, laboratories, other
The sales volume for Mar/2013 fiscal term amounted to Yen 9,441 million,
a 9% up from Yen 8,664 million in the previous term. Clinical chemistry-related products were
in good demand. Also food-testing
products fared well. The recurring
profit was posted at Yen 921 million and the net profit at Yen 1,496 million,
respectively, compared with Yen 495 million recurring profit and Yen 342
million net profit, respectively, a year ago. This term’s profits include Yen
1,514 million extraordinary profits.
For the current term ending Mar 2014 the recurring profit is projected
at Yen 930 million and the net profit at Yen 400 million, respectively, on a 5%
rise in turnover, to Yen 9,900 million.
Business is seen expanding steadily.
The financial situation is considered FAIR and good for ORDINARY
business engagements. Max credit
limit is estimated at Yen 335.7 million, on 30 days normal terms.
Date Registered:
Jul 1952
Regd No.:
0100-01-041474 (Tokyo-Chuoku)
Legal Status: Limited Company (Kabushiki Kaisha)
Authorized: 1,416,000 shares
Issued: 354,000 shares
Sum: Yen 783 million
Major
shareholders (%): Hiroshi Kikuchi (17.5), Employees’ S/Holding Assn (14.1), Sekisui
Chemical Co (11.5)
No. of shareholders: 37
Nothing
detrimental is known as to the commercial morality of executives.
Activities: Manufactures
hospital-use pharmaceuticals: Clinical chemistry & immunodiagnostics,
reagents (47%), medical equipment/instrument/devices (33%), others 20%)
Exports
(10%)
(Products
manufactured)
Clinical
chemistry & immunodiagnostics: reagents for automated analysis, manual
testing, reference standard;
Clinical
microbiology: prepared media (vitalmedia series), dehydrated powder media, drug
susceptibility testing, identification, microbacteria testing;
Cell
biology products
Food
& environment testing products
Clients: [Mfrs,
wholesalers] Alfresa Co, Toho Pharmaceutical, Mediceo Corp, Suzuken Co,
other
No. of accounts:
300
Domestic areas of
activities: Nationwide
Suppliers: [Mfrs, wholesalers]
Sekisui Chemical, Sekisui Medical, Akita Jujo Chemicals, Sanko Co, Sekisui
Polymatec, other
Payment record: No complaints
Location: Business area in
Tokyo. Office premises at the
caption address are owned and maintained satisfactorily.
Bank References: SMBC
(Kanda-Ekimae)
MUFG
(Ohdenmacho)
Relations:
Satisfactory
(In
Million Yen)
|
Terms
Ending: |
31/03/2014 |
31/03/2013 |
31/03/2012 |
31/03/2011 |
|
|
Annual
Sales |
|
9,900 |
9,441 |
8,664 |
9,401 |
|
Recur.
Profit |
|
930 |
921 |
495 |
907 |
|
Net
Profit |
|
400 |
1,496 |
342 |
505 |
|
Total
Assets |
|
|
13,377 |
11,188 |
11,126 |
|
Current
Assets |
|
|
8,444 |
6,278 |
6,171 |
|
Current
Liabs |
|
|
4,332 |
3,224 |
3,462 |
|
Net
Worth |
|
|
6,705 |
5,199 |
4,963 |
|
Capital,
Paid-Up |
|
|
783 |
783 |
783 |
|
Div.P.Share(¥) |
|
|
500.00 |
350.00 |
100.00 |
|
<Analytical Data> |
(%) |
(%) |
(%) |
(%) |
|
|
S.Growth Rate |
4.86 |
8.97 |
-7.84 |
8.42 |
|
|
Current Ratio |
.. |
194.92 |
194.73 |
178.25 |
|
|
N.Worth Ratio |
.. |
50.12 |
46.47 |
44.61 |
|
|
R.Profit/Sales |
9.39 |
9.76 |
5.71 |
9.65 |
|
|
N.Profit/Sales |
4.04 |
15.85 |
3.95 |
5.37 |
|
|
Return On Equity |
.. |
22.31 |
6.58 |
10.18 |
|
Notes: Forecast
(or estimated) figures for the 31/03/2014 fiscal term.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.61.20 |
|
|
1 |
Rs.102.35 |
|
Euro |
1 |
Rs.84.95 |
INFORMATION DETAILS
|
Report Prepared
by : |
NIS |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall
operation is considered normal. Capable to meet normal commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major sections
of this report. The assessed factors and their relative weights (as indicated
through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market
trend (10%) Operational
size (10%)